GSK 690693Cat. No. 4144 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.Special ConditionsNo more than 500 mg per individual per year to be sold without prior permission from the licence holder. |
|
Chemical Name: 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol |
Biological Activity
ATP-competitive pan-Akt kinase inhibitor (IC50 values are 2, 13 and 9 nM of Akt1, 2 and 3 respectively). Also exhibits some inhibition for AMPK, PKA and PAK and PKC isoforms (IC50 < 100 nM). Displays antiproliferative and apoptotic effects in tumor cell lines.Licensing Information
Sold for research purposes only under agreement from GlaxoSmithKlineCertificate of Analysis / Safety Data Sheet
References
Heerding et al (2008) Identification of 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{(3S)-3-piperidinylmethoxyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J.Med.Chem. 51 5663. PMID: 18800763.
Rhodes et al (2008) Characterization of an Akt inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res. 68 2366. PMID: 18381444.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: GSK 690693, supplier, GSK, 690693, inhibits, Akt, inhibitor, GSK690693, antitumor, antiproliferative
Quick Order
Find multiple products by catalog number
New Products in this Area
Cyclin-dependent kinase inhibitor
GSK2578215APotent, selective LRRK2 inhibitor; brain penetrant
AmlexanoxInhibitor of TBK1 and IKKε; antiallergic agent
PF 05212384Potent and selective dual PI 3-kinase/mTOR inhibitor
PF 03814735Aurora kinase A and B inhibitor
PF 04691502Dual PI 3-K/mTOR inhibitor
TNPInhibitor of IP6K; also inhibits IP3K
ACHPSelective IKKα and IKKβ inhibitor
PD 0332991 isethionatePotent, selective Cdk4/6 inhibitor; brain penetrant
CZC 24832Selective inhibitor of PI 3-Kinase γ
LY 333531 hydrochlorideProtein kinase C inhibitor; selective for β isozymes
PF 06465469Potent inhibitor of interleukin-2 inducible T cell kinase (ITK). Also inhibits BTK
10Z-HymenialdisinePan kinase inhibitor; potently inhibits MEK-1
CP 690550 citratePotent JAK inhibitor
WYE 687 dihydrochloridePotent and selective mTOR inhibitor
N,N-DimethylsphingosineSphingosine kinase inhibitor
PEP 005Protein kinase C activator
CZC 54252 hydrochloridePotent LRRK2 inhibitor; neuroprotective
Bisindolylmaleimide IIPotent PKC inhibitor and nicotinic receptor antagonist
CID 2011756Pan protein kinase D (PKD) inhibitor; cell permeable
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.







